Insmed’s (INSM) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Insmed (NASDAQ:INSM) in a research report sent to investors on Monday morning,Benzinga reports. The firm currently has a $220.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Insmed’s Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($1.26) EPS and FY2027 earnings at $1.63 EPS.

INSM has been the topic of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research report on Friday, July 17th. Barclays reduced their price target on Insmed from $237.00 to $207.00 and set an “overweight” rating for the company in a research report on Wednesday, September 30th. Wells Fargo & Company upped their price target on Insmed from $161.00 to $169.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Morgan Stanley reaffirmed an “overweight” rating and set a $218.00 price target on shares of Insmed in a research note on Friday, August 7th. Finally, Evercore reiterated an “outperform” rating and issued a $170.00 price objective on shares of Insmed in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $200.30.

Insmed Stock Performance

INSM opened at $97.79 on Monday. The business’s 50-day moving average price is $120.14 and its two-hundred day moving average price is $118.75. Insmed has a 1 year low of $90.39 and a 1 year high of $212.75. The company has a debt-to-equity ratio of 0.74, a current ratio of 3.72 and a quick ratio of 3.40.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.61. The company had revenue of $425.49 million for the quarter, compared to analyst estimates of $395.50 million. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%. The company’s quarterly revenue was up 296.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.70) earnings per share. On average, equities research analysts anticipate that Insmed will post -1.72 earnings per share for the current year.

Insider Transactions at Insmed

In other news, Director David R. Brennan sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total value of $3,100,000.00. Following the completion of the transaction, the director owned 39,238 shares in the company, valued at $4,865,512. This trade represents a 38.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Roger Adsett sold 239,850 shares of Insmed stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $133.27, for a total value of $31,964,809.50. Following the completion of the sale, the chief operating officer directly owned 98,744 shares in the company, valued at approximately $13,159,612.88. This represents a 70.84% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of INSM. Sei Investments Co. boosted its holdings in shares of Insmed by 56.8% in the 1st quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company’s stock valued at $228,239,000 after buying an additional 505,624 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Insmed in the second quarter valued at $139,966,000. Castle Hook Partners LP increased its holdings in Insmed by 14.9% during the fourth quarter. Castle Hook Partners LP now owns 1,253,568 shares of the biopharmaceutical company’s stock worth $218,171,000 after buying an additional 162,163 shares during the last quarter. Pictet Asset Management Holding SA increased its holdings in Insmed by 14.9% during the first quarter. Pictet Asset Management Holding SA now owns 1,102,248 shares of the biopharmaceutical company’s stock worth $178,659,000 after buying an additional 143,285 shares during the last quarter. Finally, NWI Management LP increased its holdings in Insmed by 2.6% during the first quarter. NWI Management LP now owns 1,014,000 shares of the biopharmaceutical company’s stock worth $165,809,000 after buying an additional 25,540 shares during the last quarter.

Key Stories Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: New respiratory data could strengthen the pipeline outlook. Insmed will present data at CHEST 2026 and IDWeek 2026 covering treprostinil palmitil inhalation powder (TPIP) in pulmonary hypertension, additional ASPEN bronchiectasis analyses, and ENCORE findings on resistance in MAC lung disease. The presentations could provide investors with additional evidence regarding the commercial potential of Insmed’s respiratory portfolio. Insmed respiratory portfolio data announcement
• Positive Sentiment: HC Wainwright raised its earnings forecasts and maintained a Buy rating. The firm increased its 2026 EPS estimate to a loss of $1.26 from a projected loss of $1.86, raised its fourth-quarter estimate to a loss of $0.08 from $0.49, and lifted its third-quarter estimate to a loss of $0.13 from $0.31. It also modestly increased its 2027 EPS forecast to $1.63. HC Wainwright retained a $220 price target. HC Wainwright Insmed estimates
• Neutral Sentiment: Options activity was unusually heavy. Traders purchased 8,177 call options, more than triple typical daily call volume. This may indicate increased speculative interest or expectations for a move, but it does not establish a clear direction for the shares.
• Negative Sentiment: Wolfe Research downgraded Insmed to Peer Perform from Outperform. The rating change likely contributed to recent weakness by reducing bullish analyst support and signaling that the stock’s risk-reward profile may be less attractive after its prior gains. Insmed Wolfe Research downgrade

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company’s research and development activities center on pulmonary and inflammatory conditions, with an emphasis on diseases that have limited treatment options.

Insmed’s principal commercial product is ARIKAYCE liposomal, an inhaled formulation of amikacin used with a combination antibacterial regimen to treat refractory Mycobacterium avium complex lung disease in certain adult patients.